Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A U-turn by health watchdogs means leukaemia patients will get NHS access to a new cancer drug trialled in Wales.
Those with the most common form of the blood cancer - Chronic lymphocytic leukaemia (CLL) - will now be able to have access to the drug Gazyvaro.
It was trialled by Cardiff University, and can reduce the risk of death by 59% by targeting cancer cells before they multiply.
But officials initially rejected the use of the drug two months ago.
The National Institute for Health and Care Excellence (Nice) has now provisionally approved the medicine following further analysis and the cost of the medicine being cut.
http://www.bbc.co.uk/news/uk-wales-30274804
Those with the most common form of the blood cancer - Chronic lymphocytic leukaemia (CLL) - will now be able to have access to the drug Gazyvaro.
It was trialled by Cardiff University, and can reduce the risk of death by 59% by targeting cancer cells before they multiply.
But officials initially rejected the use of the drug two months ago.
The National Institute for Health and Care Excellence (Nice) has now provisionally approved the medicine following further analysis and the cost of the medicine being cut.
http://www.bbc.co.uk/news/uk-wales-30274804